Augmented hepatic and skeletal thyromimetic effects of tiratricol in comparison with levothyroxine

Journal of Clinical Endocrinology and Metabolism

Volumn 82, Issue 7, 1997, Pages 2153-2158

  Sherman, Steven I ^a   Ringel, Matthew D ^b   Smith, Michele J ^a   Kopelen, Helen A ^c   Zoghbi, William A ^c   Ladenson, Paul W ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEVOTHYROXINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OSTEOCALCIN; THYROMIMETIC AGENT; TIRATRICOL;

ADULT; AGED; ARTICLE; BONE METABOLISM; CALCIUM EXCRETION; CLINICAL ARTICLE; DRUG ACTIVITY; DRUG EFFECT; FEMALE; HORMONE ACTION; HUMAN; LIVER METABOLISM; MALE; PRIORITY JOURNAL; URINARY EXCRETION;

ADULT; AGED; APOLIPOPROTEINS; BONE AND BONES; CARDIOVASCULAR SYSTEM; CHOLESTEROL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPOTHYROIDISM; LIVER; MALE; MIDDLE AGED; THYROTROPIN; THYROXINE; TRIIODOTHYRONINE;

EID: 0030743442     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.82.7.2153     Document Type: Article

References (53)

1. Coronary Drug Project Group. 1972 The coronary drug project. Findings leading to further modifications of its protocol with respect to dextrothyroxine. JAMA. 220:996-1008.
2. Bantle J, Oppenheimer J, Schwartz H, Hunninghake D, Probstfield J, Hanson R. 1981 TSH response to TRH in euthyroid, hypercholesterolemic patients treated with graded doses of dextrothyroxine. Metabolism. 30:63-66.
3. Young WJ, Gorman C, Jiang N, Machacek D, Hay I. 1984 L-Thyroxine contamination of pharmaceutical d-thyroxine: probable cause of therapeutic effect. Clin Pharmacol Ther. 36:781-787.
4. Underwood AH, Emmett JC, Ellis D, et al. 1986 A thyromimetic that decreases plasma cholesterol levels without increasing cardiac activity. Nature. 324:425-429.
5. Taylor AH, Steele RE, Stephan ZF, Wong NCW. Effect of a novel thyromimetic, CGS 23425, on lipoprotein metabolism [Abstract P2-1001]. Proc of the 10th Int Congr of Endocrinol. 1996; 655.
6. Pitt-Rivers R. 1953 Physiological activity of the acetic acid analogues of some iodinated thyronines. Lancet. 2:234-235.
7. Lerman JL, Pitt-Rivers R. 1956 Physiological activity of triiodo- and tetraiodothyroacetic acid inhuman myxedema. J Clin Endocrinol Metab. 16:1470-1479.
8. 3. Mol Endocrinol. 4:227-234.
9. Takeda T, Suzuki S, Liu R-T, DeGroot LJ. 1995 Triiodothyroacetic acid has unique potential for therapy of resistance to thyroid hormone. J Clin Endocrinol Metab. 80:2033-2040.
10. Madeiros-Neto G, Kallas WG, Knobel M, Cavaliere H, Mattar E. 1980 Triac (3,5,3′-triiodothyroacetic acid (TRIAC) at the pituitary and peripheral tissue levels. J Endocrinol Invest. 11:113-118.
11. Beck-Peccoz P, Sartorio A, De Medici C, Grugni G, Morabito F, Faglia G. 1988 Dissociated thyromimetic effects of 3,5,3′-triiodothyroacetic acid (TRIAC) at the pituitary and peripheral tissue levels. J Endocrinol Invest. 11:113-118.
12. Jaffiol C, Baldet L, Papachristou C, Bringer J. 1988 Value of triiodothyroacetic acid as suppressive treatment of the thyrotropin secretion in thyroid pathology. Presse Med. 17:57-60.
13. Mueller-Gaertner HW, Schneider C. 1988 3,5,3′-Triiodothyroacetic acid minimizes the pituitary thyrotrophin secretion in patients on levo-thyroxine therapy after ablative therapy for differentiated thyroid carcinoma. Clin Endocrinol (Oxf). 28:345-351.
14. Lind P, Langsteger W, Koltringer P, Eber O. 1989 3,5,3′-Triiodothyroacetic acid (TRIAC) effects on pituitary thyroid regulation and on peripheral tissue parameters. Nuklearmedizin. 28:217-220.
15. Mechelany C, Schlumberger M, Challeton C, Comoy E, Parmentier C. 1991 TRIAC (3,5,3′-triiodothyroacetic acid) has parallel effects at the pituitary and peripheral tissue levels in thyroid cancer patients treated with I-thyroxine. Clin Endocrinol (Oxf). 35:123-128.
16. Bracco D, Morin O, Schutz Y, Liang H, Jequier E, Burger AG. 1993 Comparison of the metabolic and endocrine effects of 3,5,3′-triiodothyroacetic acid and thyroxine. J Clin Endocrinol Metab. 77:221-228.
17. Sherman SI, Ladenson PW. 1992 Organ-specific effects of tiratricol: a thyroid hormone analog with hepatic, not pituitary, superagonist effects. J Clin Endocrinol Metab. 75:901-905.
18. Srinath U, Shacklock F, Shannon BM, et al. 1993 MEDFICTS: a dietary assessment instrument for evaluating fat, saturated fat, and cholesterol intake. Circulation. 88:I-634.
19. Frayn KN. 1983 Calculation of substrate oxidation rates in vivo from gaseous exchange. J Appl Physiol Respir Environ Exercise Physiol. 55:628-634.
20. Owen OE, Kavle E, Owen RS, et al. 1986 A reappraisal of caloric requirements in healthy women. Am J Clin Nutr. 44:1-19.
21. Henson LC, Poole DC, Donahoe CP, Heber D. 1987 Effects of exercise training on resting energy expenditure during caloric restriction. Am J Clin Nutr. 46:893-899.
22. Schiller NB, Shah PM, Crawsford M. 1989 Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr. 2:358-367.
23. Zoghbi WA, Galan A, Quiñones MA. 1988 Accurate assessment of aortic stenosis severity by Doppler echocardiography independent of aortic jet velocity. Am Heart J. 116:855-863.
24. Tseng KH, Walfish PG, Persaud JA, Gilbert BW. 1989 Concurrent aortic and mitral valve echocardiography permits measurement of systolic time intervals as an index of peripheral tissue thyroid functional status. J Clin Endocrinol Metab. 69:633-638.
25. Mulvagh S, Quiñones MA, Kleiman NS, Cheirif JB, Zoghbi WA. 1992 Estimation of left ventricular end-diastolic pressure from Doppler transmitral velocity in cardiac patients independent of systolic performance. J Am Coll Cardiol. 20:112-119.
26. Colan SD, Borow KM, Neumann A. 1984 Left ventricular end-systolic wall stress-velocity of fiber shortening relation: a load independent index of myocardial contractility. J Am Coll Cardiol. 4:715-724.
27. Devereux RB. 1987 Detection of left ventricular hypertrophy by M-mode echocardiography: anatomic validation, standardization, and comparison to other methods. Hypertension. 9(Suppl 2):II:19-II:26.
28. Friedewald WT, Levy RI, Fredrickson DS. 1972 Estimation of the concentration of low-density lipoprotein in plasma, without use of the preparative ultracentrifuge. Clin Chem. 18:499-502.
29. Siedel J, Hagele EO, Ziegenhorn J, Wahlefeld AW. 1983 Reagent for the enzymatic determination of serum total cholesterol with improved lipolytic efficiency. Clin Chem. 29:1075-1080.
30. Nagele U, Hagele EO, Sauer G, et al. 1984 Reagent for the enzymatic determination of serum total triglycerides with improved lipolytic efficiency. J Chem Clin Biochem. 22:165-174.
31. 2+ precipitation procedure for quantification of high density lipoprotein cholesterol. Clin Chem. 28:1379-1388.
32. Gaubatz JW, Cushing GL, Morrisett JD. 1986 Quantitation, isolation, and characterization of human lipoprotein(a). In: Albers JJ, Segrest JP, eds. Methods in Enzymology, Vol. 129: Plasma lipoproteins, Part B. Orlando; Academic Press: 167-185.
33. The Lipid Research Clinics Coronary Primary Prevention Trial results. 1984 II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 251:365-374.
34. Avogoro P, Bittolo BG, Cazzolato G, Rovai E. 1980 Relationship between apolipoprotein and chemical components of lipoprotein in survivors of myocardial infarction. Atherosclerosis. 37:69-76.
35. Raggatt LE, Blok RB, Hamblin PS, Barlow JW. 1992 Effects of thyroid hormone on sex hormone-binding globulin gene expression in human cells. J Clin Endocrinol Metab. 75:116-120.
36. Dumoulin SC, Perret BP, Bennet AP, Caron PJ. 1995 Opposite effects of thyroid hormones on binding proteins for steroid hormones (sex hormone-binding globulin and corticosteroid-binding globulin) in humans [published erratum appears in Eur J Endocrinol 1995 Sep;133(3):381]. Eur J Endocrinol. 132:594-598.
37. Takamatsu J, Majima M, Miki K, Kuma K, Mozai T. 1985 Serum ferritin as a marker of thyroid hormone action on peripheral tissues. J Clin Endocrinol Metab. 61:672-676.
38. Leedman PJ, Stein AR, Chin WW, Rogers JT. 1996 Thyroid hormone modulates the interaction between iron regulatory proteins and the ferritin mRNA iron-responsive element. J Biol Chem. 271:12017-12023.
39. Day R, Gebhard RL, Schwartz HL, et al. 1989 Time course of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase activity and messenger ribonucleic acid, biliary lipid secretion, and hepatic cholesterol content in methimazole-treated hypothyroid and hypophysectomized rats after triiodothyronine administration: possible linkage of cholesterol synthesis to biliary secretion. Endocrinology. 125:459-468.
40. Ness GC, Pendleton LC, Li YC, Chiang JY. 1990 Effect of thyroid hormone on hepatic cholesterol 7 alpha hydroxylase, LDL receptor, HMG-CoA reductase, farnesyl pyrophosphate synthetase and apolipoprotein A-I mRNA levels in hypophysectomized rats. Biochem Biophys Res Commun. 172:1150-1156.
41. De Bruin TWA, Van Barlingen H, Trip MV, De Vires ARV, Akveld MJ, Erkelens DW. 1993 Lipoprotein(a) and apolipoprotein B plasma concentrations in hypothyroid, euthyroid, and hyperthyroid subjects. J Clin Endocrinol Mctab. 76:121-126.
42. Ginsberg HN, Goldberg II. 1989 Dyslipoproteinemias in thyroid disease. In: Fruchart JC, Shepherd J, eds. Human plasma lipoproteins. Berlin: De Gruyter; 231-244.
43. Davidson NO, Carlos RC, Lukaszewicz AM. 1990 Apolipoprotein B mRNA editing is modulated by thyroid hormone analogs hut not growth hormone administration in the rat. Mol Endocrinol. 4:779-785.
44. Strobl W, Chan L, Patsch W. 1992 Differential regulation of hepatic apolipoprotein A-I and A-II gene expression by thyroid hormone in rat liver. Atherosclerosis. 97:161-170.
45. Kawaguchi H, Pilbeam CC, Raisz LG. 1994 Anabolic effects of 3,3′,5-triiodothyronine and triiodothyroacetic acid in cultured neonatal mouse parietal bones. Endocrinology. 135:971-976.
46. Kawaguchi H, Pilbeam CC, Woodiel FN, Raisz LG. 1994 Comparison of the effects of 3,5,3′-triiodothyroacetic acid and triiodothyronine on bone resorption in cultured fetal rat long bones and neonatal mouse calvariae. J Bone Miner Res. 9:247-253.
47. Fazio S, Biondi B, Carella C, et al. 1995 Diastolic dysfunction in patients on thyroid-stimulating hormone suppressive therapy with levothyroxine: beneficial effect of β-blockade. J Clin Endocrinol Metab. 80:2222-2226.
48. Schwartz HL, Lazar MA, Oppenheimer JH. 1994 Widespread distribution of irnmunoreactive thyroid hormone β2 in the nuclei of extrapituitary rat tissues. J Biol Chem. 269:24777-24782.
49. Abu EO, Bord S, Horner A, Chatterjee VKK, Compston JE. The expression of thyroid hormone receptors in human bone [Abstract M464]. Proc of the 18th Annual Meet of the Am Soc for Bone and Miner Res. 1996; S297.
50. Chamba A, Neuberger J, Strain A, Hopkins J, Sheppard MC, Franklyn JA. 1996 Expression and function of thyroid hormone receptor variants in normal and chronically diseased human liver. J Clin Endocrinol Metab. 81:360-367.
51. Sugawara A, Yen PM, Darling DS, Chin WW. 1993 Characterization and tissue expression of multiple triiodothyronine receptor-auxiliary proteins and their relationship to the retinoid-X receptors. Endocrinology. 133:965-971.
52. Petty K. 1995 Tissue- and cell-specific distribution of proteins that interact with the human thyroid hormone receptor-β. Mol Cell Endocrinol. 108:131-142.
53. Hayashi Y, Weiss RE, Same DH, et al. 1995 Do clinical manifestations of resistance to thyroid hormone correlate with the functional alteration of the corresponding mutant thyroid hormone-β receptors? J Clin Endocrinol Metab. 80:3246-3256.